共 264 条
[1]
Shepherd JH(1989)Revised FIGO staging for gynaecological cancer Br J Obstet Gynaecol 96 889-892
[2]
De Angelis R(2014)Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5-a population-based study Lancet Oncol 15 23-34
[3]
Sant M(2011)Evolution of platinum resistance in high-grade serous ovarian cancer Lancet Oncol. 12 1169-1174
[4]
Coleman MP(1991)Responses to second-line cisplatin based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin J Clin Oncol 9 1801-1805
[5]
Cooke SL(2009)Emerging role of pemetrexed in ovarian cancer Expert Rev Anticancer Ther 9 1727-1735
[6]
Brenton JD(2012)Intraperitoneal chemotherapy by ultrasound-guided direct puncture in recurrent ovarian cancer: feasibility, compliance, and complications Int J Gynecol Cancer 22 1069-1074
[7]
Markman M(2009)Treatment of recurrent epithelial ovarian cancer Ther Clin Risk Manag 5 421-426
[8]
Reichman B(2012)Current knowledge and open issues regarding bevacizumab in gynecological neoplasms Crit Rev Oncol Hematol 83 35-46
[9]
Hakes T(2014)Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer Expert Opin Investig Drugs 23 37-53
[10]
Tomao F(2013)Current status of bevacizumab in advanced ovarian cancer Onco Targets Ther. 6 889-899